NCT06356519招募中不适用
Effectiveness and Safety of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer: A Multi-center Real-world Retrospective Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 150
- 试验地点
- 1
- 主要终点
- PFS
研究概览
简要总结
The aim of this trial is to explore the real-world effectiveness and poteintial predictors of Sacituzumab Govitecan in Chinese metastatic breast cancer patients.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Patients aged over 18 years old.
- •Metastatic breast cancer included unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer.
- •Plan to receive or has received Sacituzumab Govitecan monotherapy
- •Available medical history.
排除标准
- •Incomplete medical history.
- •Pregnancy or breast-breeding
研究组 & 干预措施
Sacituzumab Govitecan
Sacituzumab Govitecan,10 mg/kg ivgtt d1, d8, q3w
干预措施: Sacituzumab Govitecan (Drug)
结局指标
主要结局
PFS
时间窗: 6 weeks
Progression free survival
次要结局
- OS(6 weeks)
- ORR(6 weeks)
- Number of participants with treatment-related adverse events as assessed by CTCAE v5.0(6 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast CancerMetastatic Breast CancerNCT03901339Gilead Sciences543
招募中
2 期
Sacituzumab Govitecan for Advanced Esophageal Squamous Cell CarcinomaEsophageal Squamous Cell CarcinomaNCT06329869National Taiwan University Hospital35
招募中
2 期
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBCBreast CancerHormone-receptor-positive Breast CancerHuman Epidermal Growth Factor 2 Low Breast CancerAdvanced Breast CancerMetastatic Breast CancerNCT06263543Reshma L. Mahtani, D.O.75
进行中（未招募）
2 期
A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)Her 2 Positive Breast CancerBreast Cancer FemaleBreast Cancer MetastaticNCT06100874Adrienne G. Waks28
进行中（未招募）
2 期
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has SpreadMetastatic Urothelial CancerNCT03547973Gilead Sciences502